Semaglo-OB
Generic Name
Semaglutide
Manufacturer
Global Pharma Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| semaglo ob 05 mg injection | ৳ 700.00 | N/A |
Description
Overview of the medicine
Semaglo-OB 0.5 mg Injection contains Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, used for the treatment of type 2 diabetes mellitus to improve glycemic control in adults. It may also be indicated for chronic weight management in certain patients.
Uses & Indications
Dosage
Adults
The starting dose is 0.25 mg once weekly for 4 weeks. After 4 weeks, increase to 0.5 mg once weekly. The 0.5 mg dose is often a maintenance dose or a step in further dose escalation depending on individual response and tolerability, up to a maximum of 2.0 mg once weekly.
Elderly
No dose adjustment is required based on age; however, monitor for gastrointestinal side effects.
Renal_impairment
No dose adjustment is needed for patients with mild, moderate, or severe renal impairment. Caution is advised in patients with end-stage renal disease.
How to Take
Administer Semaglo-OB 0.5 mg Injection subcutaneously once weekly, at any time of day, with or without meals. Inject into the abdomen, thigh, or upper arm. Rotate injection sites.
Mechanism of Action
Semaglutide acts as a GLP-1 receptor agonist, mimicking the effects of natural GLP-1. It enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon secretion, slows gastric emptying, and reduces food intake by increasing satiety, thereby lowering blood glucose and promoting weight loss.
Pharmacokinetics
Onset
Glycemic effects begin within a few hours, but steady-state plasma concentrations are reached after 4-5 weeks of once-weekly administration.
Excretion
Primary excretion routes are urine (approx. 2/3) and feces (approx. 1/3) after metabolic degradation. Only a small fraction is excreted unchanged.
Half life
Approximately 1 week (about 7 days), allowing for once-weekly dosing.
Absorption
Slow absorption after subcutaneous administration, reaching peak plasma concentrations 1-3 days post-dose.
Metabolism
Metabolized extensively through proteolytic cleavage of the peptide backbone and subsequent beta-oxidation of the fatty acid side chain, not involving cytochrome P450 enzymes.
Side Effects
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC).
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to semaglutide or any components of the product.
Drug Interactions
Oral medications
Semaglutide slows gastric emptying, which may affect the absorption of concomitantly administered oral medications. Monitor patients taking oral medications with a narrow therapeutic index or those requiring rapid gastrointestinal absorption.
Storage
Store unopened pens in a refrigerator (2°C to 8°C). Do not freeze. After first use, store at room temperature (below 30°C) or in the refrigerator (2°C to 8°C) for up to 6 weeks. Keep the pen cap on to protect from light.
Overdose
In case of overdose, patients may experience severe nausea, vomiting, or hypoglycemia. Treatment should be supportive and symptomatic. Monitor blood glucose levels, especially if co-administered with insulin or sulfonylurea.
Pregnancy & Lactation
Pregnancy Category C/X (depending on brand/country guidance). Should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. Discontinue at least 2 months before planned pregnancy. It is unknown whether semaglutide is excreted in human milk; avoid use during lactation.
Side Effects
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC).
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to semaglutide or any components of the product.
Drug Interactions
Oral medications
Semaglutide slows gastric emptying, which may affect the absorption of concomitantly administered oral medications. Monitor patients taking oral medications with a narrow therapeutic index or those requiring rapid gastrointestinal absorption.
Storage
Store unopened pens in a refrigerator (2°C to 8°C). Do not freeze. After first use, store at room temperature (below 30°C) or in the refrigerator (2°C to 8°C) for up to 6 weeks. Keep the pen cap on to protect from light.
Overdose
In case of overdose, patients may experience severe nausea, vomiting, or hypoglycemia. Treatment should be supportive and symptomatic. Monitor blood glucose levels, especially if co-administered with insulin or sulfonylurea.
Pregnancy & Lactation
Pregnancy Category C/X (depending on brand/country guidance). Should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. Discontinue at least 2 months before planned pregnancy. It is unknown whether semaglutide is excreted in human milk; avoid use during lactation.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
2-3 years (unopened, refrigerated). 6 weeks (after first use, stored at room temperature or refrigerated).
Availability
Available in pharmacies and hospitals
Approval Status
Approved by major regulatory bodies (e.g., FDA, EMA)
Patent Status
Patented (original compound)
WHO Essential Medicine
YesClinical Trials
Extensive clinical trials (e.g., SUSTAIN program for diabetes, STEP program for weight management) have demonstrated the efficacy and safety of semaglutide in improving glycemic control and achieving weight loss.
Lab Monitoring
- HbA1c levels (every 3-6 months)
- Fasting plasma glucose
- Renal function (periodically)
- Pancreatic enzymes (if pancreatitis is suspected)
Doctor Notes
- Educate patients thoroughly on the proper subcutaneous injection technique and the importance of weekly dosing.
- Counsel patients on potential gastrointestinal side effects and management strategies.
- Advise patients to seek immediate medical attention for symptoms of pancreatitis (severe abdominal pain), gallbladder disease, or allergic reactions.
Patient Guidelines
- Learn proper injection technique from a healthcare professional.
- Store the pen correctly and check the expiration date.
- Never share your Semaglo-OB pen with another person, even if the needle is changed, as this carries a risk of infection.
- Report any severe abdominal pain, vision changes, or signs of allergic reaction immediately.
Missed Dose Advice
If a dose is missed, administer it as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. Do not take two doses within 48 hours.
Driving Precautions
Semaglo-OB alone does not typically cause hypoglycemia. However, if used in combination with insulin or a sulfonylurea, the risk of hypoglycemia increases, which can impair ability to drive or operate machinery. Be cautious if you experience symptoms of hypoglycemia.
Lifestyle Advice
- Maintain a balanced diet and follow a reduced-calorie meal plan.
- Engage in regular physical activity as advised by your doctor.
- Monitor blood glucose levels regularly as instructed.
- Maintain adequate hydration.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Semaglo-OB Brand
Other medicines available under the same brand name
Semaglo-OB
Solution for injection (pre-filled pen)
Semaglo-OB
Subcutaneous Injection
Semaglo-OB
Solution for subcutaneous injection
Semaglo-OB
Injection (Subcutaneous)